Verastem (VSTM) investor relations material

Key product launches and commercial progress

• Achieved accelerated FDA approval for avutometinib plus defactinib in low-grade serous ovarian cancer, with a 44% response rate in pivotal study and over $2 million net sales in the first six weeks post-launch.

• Strong momentum continues into the first full quarter, with positive feedback from physicians and patients.

• No immediate plans for Canada; regulatory discussions ongoing in Europe and Japan, with a bridging study in Japan nearing full accrual and potential conditional approval targeted for 2027.

Clinical development and pipeline updates

• Confirmatory Phase 3 trial in ovarian cancer is nearly fully accrued, with a pre-planned interim analysis expected later this year to assess sample size and study direction.

• Expansion of avutometinib plus defactinib into other indications, including G12C non-small cell lung cancer (in partnership with Amgen) and frontline metastatic pancreatic cancer, with 83% response rate in the latter.

• VS-7375, a dual on-off KRAS G12D inhibitor, shows promising data from partner GenFleet Therapeutics: 52% response rate in pancreatic cancer and 69% in lung cancer at recommended dose.

• U.S. Phase 1 for VS-7375 is progressing rapidly, with safety data expected later this year and initial efficacy data in the first half of next year; combination regimens to begin soon.

Financial position and strategic outlook

• Cash position over $160 million, with an additional $50 million expected from in-the-money warrants, providing runway into the second half of 2026.

• LGSOC business could become self-funding by 2026; future funding for G12D program may come from sales, partnerships, or equity raises, with partnerships preferred over dilution.

• Additional line of credit available but not yet drawn; financial strategy will adapt to data, sales, and macroeconomic conditions.